Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharma-Bio ServPBSV -27.16%43 EPS without NRI is $0.00 as of Apr. 2026. GuruFocus rates PBSV with a GF Score™ of 43/100 and a GF Value™ of $0.58 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 508 Healthcare Providers & Services companies, Pharma-Bio Serv ranks worse than 196850.2% on this metric.
Pharma-Bio Serv's earnings per share without non-recurring items for the
three
months ended in Apr. 2026 was $0.01.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Apr. 2026 was $0.00.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Pharma-Bio Serv's EPS without NRI or its related term are showing as below:
During the past 13 years, Pharma-Bio Serv's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 130.10% per year. The lowest was -43.10% per year. And the median was -13.80% per year.
PBSV's 3-Year EPS without NRI Growth Rate is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 11.3 * Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
Pharma-Bio Serv's EPS (Diluted) for the
three
months ended in Apr. 2026 was $0.01.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Apr. 2026 was $0.00.
Pharma-Bio Serv's EPS (Basic) for the
three
months ended in Apr. 2026 was $0.01.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Apr. 2026 was $0.00.
Pharma-Bio Serv (OTCPK:PBSV) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Pharma-Bio Serv EPS without NRI Related Terms
Pharma-Bio Serv EPS without NRI Historical Data
* Premium members only.
The historical data trend for Pharma-Bio Serv's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PBSV vs MGRX, BFRG, VYND: EPS without NRI Comparison
For the Health Information Services subindustry, Pharma-Bio Serv's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharma-Bio Serv PE Ratio without NRI vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Pharma-Bio Serv's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Pharma-Bio Serv's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharma-Bio Serv (PBSV) has a EPS without NRI of $0.00 as of Apr. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Pharma-Bio Serv and its competitors. According to the industry distribution chart, Pharma-Bio Serv ranks #999999 out of 508 companies in the Healthcare Providers & Services industry.
Is Pharma-Bio Serv's EPS without NRI too high?
Pharma-Bio Serv's current EPS without NRI is $0.00. Based on the distribution chart, Pharma-Bio Serv ranks #999999 out of 508 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Pharma-Bio Serv has a GF Score™ of 43/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharma-Bio Serv's EPS without NRI compare to MGRX and BFRG?
According to the Healthcare Providers & Services industry distribution chart, Pharma-Bio Serv ranks #999999 out of 508 companies for EPS without NRI. This places Pharma-Bio Serv in the lower half of its industry. The industry median EPS without NRI is 11.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Healthcare Providers & Services company?
The median EPS without NRI among Healthcare Providers & Services companies is 11.30, based on 508 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Pharma-Bio Serv and its competitors. For the Healthcare Providers & Services industry, the median EPS without NRI is 11.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharma-Bio Serv's current EPS without NRI is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma-Bio Serv stock overvalued right now?
Based on GuruFocus' analysis, Pharma-Bio Serv (PBSV) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.58, compared to a current price of $0.42 — trading 27.2% below its estimated fair value. The current EPS without NRI is $0.00. Pharma-Bio Serv's overall GF Score™ is 43/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Pharma-Bio Serv (PBSV), the current EPS without NRI is $0.00 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharma-Bio Serv (PBSV) Overvalued in 2026?
Based on GuruFocus' analysis, Pharma-Bio Serv stock appears to be undervalued.
The current stock price of $0.42 is trading 27.2% below its estimated GF Value™ of $0.58.
GuruFocus considers Pharma-Bio Serv to be Modestly Undervalued.
Key valuation signals for PBSV:
EPS without NRI: $0.00
GF Value™: $0.58 vs. price of $0.42 (27.2% below fair value)
No single metric tells the full story. See the PBSV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharma-Bio Serv Inc is a compliance and technology transfer services consulting firm. It also provides microbiological testing services and chemical testing services through its laboratory testing facility in Puerto Rico. It has three reportable segments: Puerto Rico technical compliance consulting which is the key revenue driver; United States technical compliance consulting; and Europe technical compliance consulting. The company offers solutions to the pharmaceutical, chemical, biotechnology, medical devices, cosmetic and food industries, and allied products companies. It generates maximum revenue from Puerto Rico and also has its presence in United States, Europe and Other countries.
43GF Score
Get the complete analysis for PBSV
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBSV has been successfully added to your 
